Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211382 | 0.88 | MAPT (0.53) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL430629 | 0.86 | MAPT (0.59) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL16840490 | 0.85 | SMN1; SMN2 (0.56) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL28095926 | 0.85 | MAPT (0.49) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| Bromide SCHEMBL20984702 | 0.83 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| Hydrochloric Acid SCHEMBL20984395 | 0.83 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL9742270 | 0.82 | MAPT (0.56) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL14387817 | 0.82 | SMN1; SMN2 (0.60) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL4930929 | 0.82 | MAPT (0.68) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 | |
| SCHEMBL6300775 | 0.82 | SMN1; SMN2 (0.53) | AKR1C3AKR1C2SMN1; SMN2AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12162871-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11787791-B2 | Inhibitors of VAP-1 | ACUCELA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4201927-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Chengdu Fanxi Biopharma Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023274251-A1 | POLYCYCLIC COMPOUND FOR INHIBITING RNA HELICASE DHX33, AND APPLICATION OF COMPOUND | 深圳开悦生命科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2021-12-16 | — | — | US | disclosed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6159997-A | Treatment of arteriosclerosis and xanthoma | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5798375-A | ADMINISTERING TO THE PATIENT PREVASTATIN A HYDROXY-3-METHYL-GLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR AND A INSULIN SENSITIZER TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 1998-08-25 | — | — | US | disclosed |
| EP-0753298-A1 | Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis | SANKYO COMPANY LIMITED (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0315959-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-03-02 | — | — | EP | disclosed |
| US-5026704-A | Neuroleptic agent, quisqualate-antagonist | NOVO NORDISK A/S (DK) | 1991-06-25 | — | — | US | disclosed |
| US-4948794-A | NEUROLEPTIC AGENTS | A/S FERROSAN (DK) | 1990-08-14 | — | — | US | disclosed |
| EP-0315959-A2 | Quinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630536-B2 | Cyanotriazine derivative, preparation method therefor, and application thereof | THRB, SLC10A1, THRA | AKR1C3 611/4885AKR1C2 464/4885SMN1; SMN2 4723/4885 |
| US-11787791-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | AKR1C3 4526/4885AKR1C2 4410/4885SMN1; SMN2 2418/4885 |
| US-20230295140-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | AKR1C3 4526/4885AKR1C2 4410/4885SMN1; SMN2 2418/4885 |
| US-20230312527-A1 | CYANOTRIAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, SLC5A1, SLC10A1 | AKR1C3 1338/4885AKR1C2 496/4885SMN1; SMN2 4868/4885 |
| US-20210387975-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | AKR1C3 4526/4885AKR1C2 4410/4885SMN1; SMN2 2418/4885 |
| US-12162871-B2 | Inhibitors of VAP-1 | VAPB, VAPA, TOE1 | AKR1C3 4526/4885AKR1C2 4410/4885SMN1; SMN2 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.